Marinus Pharmaceuticals, Inc. – NASDAQ:MRNS

Marinus Pharmaceuticals stock price today

$0.55
+0.17
+48.02%
Financial Health
0
1
2
3
4
5
6
7
8
9

Marinus Pharmaceuticals stock price monthly change

-72.92%
month

Marinus Pharmaceuticals stock price quarterly change

-72.92%
quarter

Marinus Pharmaceuticals stock price yearly change

-96.62%
year

Marinus Pharmaceuticals key metrics

Market Cap
12.57M
Enterprise value
179.03M
P/E
-14.62
EV/Sales
7.02
EV/EBITDA
-33.54
Price/Sales
12.39
Price/Book
2.72
PEG ratio
-0.18
EPS
-2.63
Revenue
28.28M
EBITDA
-131.78M
Income
-145.34M
Revenue Q/Q
-26.02%
Revenue Y/Y
30.52%
Profit margin
-77.78%
Oper. margin
-442.69%
Gross margin
87.05%
EBIT margin
-442.69%
EBITDA margin
-465.87%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Marinus Pharmaceuticals stock price history

Marinus Pharmaceuticals stock forecast

Marinus Pharmaceuticals financial statements

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS): Profit margin
Jun 2023 6.08M -31.93M -525.14%
Sep 2023 7.33M -32.97M -449.33%
Dec 2023 7.19M -41.76M -580.93%
Mar 2024 7.67M -38.66M -503.57%
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS): Analyst Estimates
Mar 2024 7.67M -38.66M -503.57%
Sep 2025 13.54M -15.30M -112.97%
Oct 2025 14.46M -11.74M -81.22%
Dec 2025 20.54M -8.52M -41.51%
  • Analysts Price target

  • Financials & Ratios estimates

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS): Debt to assets
Jun 2023 201200000 143.86M 71.5%
Sep 2023 200806000 146.26M 72.84%
Dec 2023 170908000 154.14M 90.19%
Mar 2024 137350000 153.78M 111.97%
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS): Cash Flow
Jun 2023 -24.35M 5.00M 237K
Sep 2023 -25.17M 11.92M 25.90M
Dec 2023 -26.99M 6.46M 661K
Mar 2024 -37.46M 20.88M 257K

Marinus Pharmaceuticals alternative data

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS): Employee count
Aug 2023 151
Sep 2023 151
Oct 2023 151
Nov 2023 151
Dec 2023 151
Jan 2024 151
Feb 2024 151
Mar 2024 165
Apr 2024 165
May 2024 165
Jun 2024 165
Jul 2024 165

Marinus Pharmaceuticals other data

81.68% +0.23%
of MRNS is owned by hedge funds
29.94M +18.77K
shares is hold by hedge funds

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS): Insider trades (number of shares)
Period Buy Sel
Aug 2023 0 16725
Feb 2024 0 21803
Transaction Date Insider Security Shares Price per share Total value Source
Option
BRAUNSTEIN SCOTT director, officer.. Common Stock 50,000 $4.28 $214,000
Option
BRAUNSTEIN SCOTT director, officer.. Stock Option (Right to Buy) 50,000 $4.28 $214,000
Sale
SHAFER CHRISTINA officer: CHIEF COMMERCIAL OFFICER
Common Stock 2,153 $9.56 $20,583
Sale
MANNING MARTHA E officer: SVP, GEN. COUNSEL & CO..
Common Stock 1,894 $9.57 $18,126
Sale
HULIHAN JOSEPH officer: CHIEF ME.. Common Stock 2,814 $9.98 $28,084
Sale
PFANSTIEL STEVEN officer: CFO AND COO
Common Stock 3,092 $9.97 $30,827
Sale
BRAUNSTEIN SCOTT director, officer.. Common Stock 11,850 $9.94 $117,789
Sale
SHAFER CHRISTINA officer: CHIEF COMMERCIAL OFFICER
Common Stock 11 $8.93 $98
Sale
BRAUNSTEIN SCOTT director, officer.. Common Stock 30 $8.94 $268
Sale
PFANSTIEL STEVEN officer: CFO AND COO
Common Stock 14 $8.93 $125
Patent
Application
Filling date: 26 Apr 2022 Issue date: 25 Aug 2022
Application
Filling date: 24 Mar 2022 Issue date: 11 Aug 2022
Application
Filling date: 1 Mar 2022 Issue date: 7 Jul 2022
Grant
Filling date: 6 Dec 2019 Issue date: 8 Mar 2022
Grant
Filling date: 26 Feb 2021 Issue date: 7 Sep 2021
Grant
Filling date: 2 Oct 2018 Issue date: 27 Jul 2021
Application
Filling date: 26 Feb 2021 Issue date: 24 Jun 2021
Grant
Filling date: 25 Mar 2020 Issue date: 11 May 2021
Application
Filling date: 13 Aug 2020 Issue date: 6 May 2021
Grant
Filling date: 14 Oct 2016 Issue date: 22 Sep 2020
Monday, 30 December 2024
businesswire.com
businesswire.com
businesswire.com
Tuesday, 12 November 2024
zacks.com
Thursday, 17 October 2024
businesswire.com
Wednesday, 16 October 2024
benzinga.com
Tuesday, 15 October 2024
businesswire.com
Friday, 11 October 2024
marketbeat.com
Wednesday, 9 October 2024
businesswire.com
Tuesday, 8 October 2024
businesswire.com
Tuesday, 1 October 2024
marketbeat.com
Friday, 20 September 2024
businesswire.com
Monday, 19 August 2024
businesswire.com
Tuesday, 13 August 2024
seekingalpha.com
zacks.com
businesswire.com
businesswire.com
Wednesday, 7 August 2024
accesswire.com
Tuesday, 6 August 2024
accesswire.com
investorplace.com
Monday, 5 August 2024
accesswire.com
globenewswire.com
accesswire.com
accesswire.com
accesswire.com
accesswire.com
prnewswire.com
Sunday, 4 August 2024
accesswire.com
accesswire.com
accesswire.com
  • What's the price of Marinus Pharmaceuticals stock today?

    One share of Marinus Pharmaceuticals stock can currently be purchased for approximately $0.55.

  • When is Marinus Pharmaceuticals's next earnings date?

    Unfortunately, Marinus Pharmaceuticals's (MRNS) next earnings date is currently unknown.

  • Does Marinus Pharmaceuticals pay dividends?

    No, Marinus Pharmaceuticals does not pay dividends.

  • How much money does Marinus Pharmaceuticals make?

    Marinus Pharmaceuticals has a market capitalization of 12.57M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 21.63% to 30.99M US dollars.

  • What is Marinus Pharmaceuticals's stock symbol?

    Marinus Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "MRNS".

  • What is Marinus Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Marinus Pharmaceuticals?

    Shares of Marinus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Marinus Pharmaceuticals's key executives?

    Marinus Pharmaceuticals's management team includes the following people:

    • Dr. Scott N. Braunstein M.D. Chief Executive Officer, Pres & Director(age: 62, pay: $898,880)
    • Dr. Joseph Hulihan M.D. Chief Medical Officer(age: 69, pay: $488,870)
  • How many employees does Marinus Pharmaceuticals have?

    As Jul 2024, Marinus Pharmaceuticals employs 165 workers.

  • When Marinus Pharmaceuticals went public?

    Marinus Pharmaceuticals, Inc. is publicly traded company for more then 11 years since IPO on 31 Jul 2014.

  • What is Marinus Pharmaceuticals's official website?

    The official website for Marinus Pharmaceuticals is marinuspharma.com.

  • Where are Marinus Pharmaceuticals's headquarters?

    Marinus Pharmaceuticals is headquartered at 5 Radnor Corporate Center, Radnor, PA.

  • How can i contact Marinus Pharmaceuticals?

    Marinus Pharmaceuticals's mailing address is 5 Radnor Corporate Center, Radnor, PA and company can be reached via phone at +48 48014670.

Marinus Pharmaceuticals company profile:

Marinus Pharmaceuticals, Inc.

marinuspharma.com
Exchange:

NASDAQ

Full time employees:

165

Industry:

Biotechnology

Sector:

Healthcare

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

5 Radnor Corporate Center
Radnor, PA 19087

CIK: 0001267813
ISIN: US56854Q2003
CUSIP: 56854Q200